Maybe, I just noticed irwd the other day, funds own 118%, short interest down 5 million, sales of their one drug growing q/q through various partners, mainly Forest labs.
LINZESS net product sales, as reported by Forest Laboratories, Inc., were $51.0 million in the fourth quarter of 2013, an increase of approximately 48% quarter over quarter, and $118.8 million for the year ended December 31, 2013.
• LINZESS net product sales, as reported by Forest Laboratories, Inc., were $60.8 million in the first quarter of 2014, an increase of approximately 19% quarter over quarter.
So at 60m Q1 = 240 annual, a double from 2013 sales of 118.
Their pipeline appears smallish and much around this one drug, but looks like they have a global plan for the drug with partners other than forest, maybe double the 240, to 480M if global plan works. It is worth following, but I am not in a position to jump in at this point.
I can't speak to all the technical, but you want a nice chart look at ironwood pharma, irwd. Not sure if this heads to all time highs, or is ready to top, but the chart is awesome.
I just noticed arry went from 1.6m, to over 4m, both arry and opk are Russel members, wonder if the Friday rebalance cleared today and some how that influenced these numbers?
A fund could easily say, ok, mine are now available for x interest, plus not sure how it works for trades to clear, for me it is 3 days, so you might be seeing the availability go up from trades that occurred a couple days ago that cleared today. Just a thought.
Available shares have to be made available by a person or institution willing to lend. The number moves around, but this is way more than usual. This might be part of the shares exchanged from the note offering hitting a fund too, no way to tell where they magically appeared from, just KNOW they are not Dr. Frost's, lol.
When a short covers 1,400,000 those shares are back in the available to short pool. When no one is covering, the number of available shares to short shrinks. If every available share to short is shorted there is zero available, if someone covers 100 shares, then that 100 becomes available again. The other factor is shares entering margin accounts, and fund buys, most funds lend out. So if a fund upped their position the availability moves up.
Not until you mentioned it. That fund that upped it's stake in arry, I looked over a few of their holdings, it is a bio only fund. A new buy was ccxi, up as arry past two days, range 4.57-14.75, currently 5.97, it is sort of interesting too.
The market is up big, the last time arry saw 4.75 was April 1, Can get to 5.00 if flippers and shorts give it a rest. Since April 1, only 2 million more shorts added, ie., are under water, some others need lock in profits to give it that push lol. 16.4 m short, 14m profitable. Time to take some off the table.
diejour, your comment makes no sense. " What if he is wrong " This is not a test where you get a paper back with red marks on the wrong answers. It is a company that is evolving with new parts being added and being developed constantly. Some will likely fail, be sold off ( as optics was ), some will be merged with bigger pharma in time. Frost will keep adding and subtracting as he always has done until he has the right mix of successful divisions, it will take time. He has the knowledge, connections and the MONEY to make his PROJECT work. This is a guy who handed OPKO for free 900K shares of stock from his personal holdings. Might seem small but taking his cash and handing it over to his company shows commitment to the company and the BALANCE sheet. The drugs in the pipeline currently are the type few others are pursuing and many are long acting versions of established items, one needle a week, not 7 a week, um, Frost knows what he is doing, not sure betting against this guy has ever worked in the long run, in fact I know it hasn't, see Key, see Ivax, and others.
Arry is in about 20 etfs, and was added to the Russell some time ago. Google alletf to see the etf funds holding any stock.
CL, You should do whatever you think is in your best financial interest. I trade neither, established my positions, so that is it for me. Opk is a stealth stock, their portfolio is considered mediocre, weak, etc., it will destroy estimates, Frost is in areas nobody is bothering with at all, competition is non existent for their ckd products.
Arry, has a far wider net, broad portfolio, in crowded markets. Arry's drugs have bling, and arry might out perform opk in the next 18 months, I am leaning that way. By eoy 2016, early 2017 opk gets respect. By early 2017 I think opko is by far the better bet, but one home run here, or a buy out in a year ( likely ) arry wins the mile, opko the marathon.
Keeping shares in each is a hedge.
If you look at this funds holdings arry is now their 3rd largest holding, was 4th. They only own 28 positions so this is a BIG bet on their part.
Rayaldy may be a catalyst, not sure the market fully gets the potential revenue of Rayaldy, thinking there are many doubters. They will be proven wrong, time will fix any misconception.
Hit 4.52 for the first time since April 4th during the bio sell off, a week ago hit 4.48 first time since April 10, so it is attempting to recover. The highest close since April 4th 4.45 about 8 days ago, needs get over and close above 4.45. 4.50 works, maybe by Wed. Hitting 4.52 bodes well, so the guy saying back to 5+ is on track.
Yes at .30 downside is limited, I do expect financing, maybe a note, ala opko type, also RS split not off the table to uplist it to a different exchange, 1 for 20 only gets it to 6.00, unless it runs back over a buck. It has been in a slow fall for quite a while. Maybe when they start phase 1, it gets a pop. good luck with it.How about TRXC ? U own that one?
Waiting4, I have no reason to print out your post, would never call you a liar. I would love to see this run, it has run in July in both 2012 and 2013, but in those years it also got an asco pop. Seems the catalysts that moved this in the past no longer are working, so figure it might take real news. Need see it get over 4.50 on volume before I believe it can continue, so far it has struggled at 4.48 and failed to break out. I am long and patient, but not adding.
Opinion? Not really, but at .30 it is worth a flyer. The technology is interesting for sure. Has Teva and Frost holding their hand so big brothers might help them along. Interesting that opko owns or has an interest in a Taiwan company that is ALSO targeting the common cold. Opko took an interest about two years ago and has to pay X a year to aid the research yet nothing is ever said about any progress. Cocp will need more cash in about 1 year, a reverse split is not off the table. Not one drug even in phase one, but planned, so it is a multi-year investment, 10-12, unless a buyer wants their patent library. The low volume and not too large share count could make this an easy double on any SA manipulative article. Though the technology will likely work it will take a lot of time and patience to see it through. Planned phase 1 studies, hep c first, influenza? then common cold, 2015, 2016, 2017 I think.